|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The prognostic impact of TERT mutations has been controversial in IDH-wild tumors, particularly in glioblastomas (GBM).
|
27503138 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter.
|
12915632 |
2003 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In particular, mutations of the telomere binding proteins alpha thalassemia/mental retardation syndrome X-linked (ATRX) or death-domain associated protein (DAXX) have been shown to underlie a telomere maintenance mechanism not involving telomerase (alternative lengthening of telomeres), and point mutations in the promoter of the telomerase reverse transcriptase (TERT) gene increase telomerase expression and have been shown to occur in melanomas and a small number of other tumors.
|
23530248 |
2013 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Data were available on 67 TERT locus polymorphisms and 24 tumor types, for a total of 221 unique combinations of polymorphisms and cancer types.
|
22523397 |
2012 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A total of 378 breakpoints common to the primary tumor and cfDNA of any given patient were identified, 27 breakpoints were seen by tumor aCGH, and 54 breakpoints were seen in cfDNA only, including two cases with interstitial IGFR1 gains and two alterations targeting TERT CONCLUSIONS: These results demonstrate the feasibility of cfDNA copy number profiling in neuroblastoma patients, with a concordance of the overall genomic profile in aCGH and cfDNA dynamic cases of 97% and a sensitivity of 77%, respectively.
|
27440268 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In the present study, 128 primary glioblastoma patients were examined for single nucleotide polymorphisms of TERT in blood and in 92 cases for TERT promoter mutations in tumors.
|
26143636 |
2015 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Single-nucleotide polymorphisms rs421629 on 5p15.33 and rs1948, rs660652, rs8040868 and rs2036527 on 15q25.1, previously identified as lung cancer risk or nicotine-addiction modifiers, were associated with tumor DNA methylation levels in the promoters of TERT and CHRNB4 (P<0.001), respectively, in two independent sample sets (n=82; n=150).
|
22945651 |
2013 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Secondary genetic alterations overcome tumor suppressive mechanisms and allow the progression to intermediate lesions characterized by TERT-p mutation or to invasive melanomas displaying disruption of tumor suppressor genes.
|
30069451 |
2018 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
TERT and CTNNB1 mutations were found more frequently in HCV related (53.6% and 26.4%, respectively) than HBV related (41.7% and 16.7%, respectively) HCCs and coexisted in 57.6% of CTNNB1 mutated tumors.
|
27276713 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here we show that this locus including the gene encoding the telomerase reverse-transcriptase TERT at 5p13.33 is rarely but recurrently targeted by somatic chromosomal translocations to IGH and non-IG loci in B-cell neoplasms, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma and splenic marginal zone lymphoma.
|
20460502 |
2010 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Multivariate analysis incorporating tumor status based on the presence of <i>IDH</i> mutations, <i>TERT</i> promoter mutations, and 1p/19q codeletion showed that in lower-grade gliomas, high NLR predicted poorer survival for the triple-negative, IDH mutation only, TERT mutation only, and IDH and TERT mutation groups.
|
31444316 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Ratios of uptake in tumor to uptake in contralateral region of hTERT-targeted siRNA were significantly higher than those of control siRNA (P < 0.05) at each time point.
|
20484428 |
2010 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
These new findings should spur new interest in the development of TERT-based immunotherapies that are redesigned in line with established immunological considerations and working principles, and are tailored to patients stratified on the basis of TERT-promoter mutations and other underlying tumour characteristics.
|
27245281 |
2017 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Telomerase reverse transcriptase promoter mutations are found in almost half of ocular surface squamous neoplasias and have a mutation profile supporting UV induction as the major source of mutagenesis.
|
26348634 |
2015 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We previously reported a disease segregating causal germline mutation in a melanoma family and recurrent somatic mutations in metastasized tumours from unrelated patients in the core promoter region of the telomerase reverse transcriptase (TERT) gene.
|
24569790 |
2014 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
TERT mutation was associated with older mean age at diagnosis (P < 0.001), larger mean tumor diameter (P = 0.013), and greater likelihood of both BRAF mutation coexistence (P = 0.044) and radioiodine-refractory character (P < 0.001).
|
27493271 |
2017 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Tumor sequencing studies further indicate that acquired somatic mutations of TERT and ATRX are among the most frequent alterations found in adult gliomas.
|
26014050 |
2015 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Interestingly, in some studies, TERT mutations were found to be more common in tumors with a BRAF(V600E) mutation.
|
27184112 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Telomerase reverse transcriptase (<i>TERT</i>) promoter mutations have been linked to adverse clinical parameters in thyroid cancer, but <i>TERT</i>-expressing tumours are not always mutated.
|
29692346 |
2018 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
NGS of the tumor showed an NRAS mutation (c.182A>G:p.Q61R) in 78%, a TP53 mutation (c.856G>A:p.E286K) in 60%, and a TERT gene mutation (1295250C>T) in 28% of the reads.
|
28973495 |
2017 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
TERT mutational status was correlated with BRAF mutation, definitive histology, and post-operative TNM staging of the neoplasia.
|
25951319 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Hallmark SHH focal copy number aberrations and chromosome 10q deletion were mutually exclusive with TERT mutations within SHH tumors.
|
24174164 |
2013 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Tumor-associated seizures are less common in TERT mutated glioblastomas.
|
28894890 |
2017 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Herein, we review the genomic profiles that have been defined for the different subtypes of pediatric melanoma and particularly emphasize the potential prognostic value of telomerase reverse transcriptase alterations for these tumors.
|
28895292 |
2018 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Among the canonical cancer-associated genes, only telomerase reverse transcriptase (TERT) promoter mutations were observed in the founding clone in all tumors.
|
29244145 |
2018 |